Form 4 for MIRM Mirum Pharmaceuticals, Inc.
Accepted 2025-08-08 00:00:00 ET · period of report 2025-08-07 · accession 0001415889-25-021350 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-08-08 | 2025-08-07 | MIRM | Peetz Christopher | CEO, Dir | S - Sale+OE | $55.25 | -40.0K | 138.6K | -22% | -$2.21M |
| D | 2025-08-08 | 2025-08-07 | MIRM | Peetz Christopher | CEO, Dir | M - OptEx | $2.94 | +40.0K | 178.6K | +29% | +$117.6K |
| D | 2025-08-08 | 2025-08-07 | MIRM | Peetz Christopher | CEO, Dir | M - OptEx | $0.00 | -40.0K | 198.5K | -17% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-08-07 | S | D | 40,000 | $55.25 | 138,641 | D | — | — | (F2) The weighted average sale price for the transaction reported was $55.251022, and the range of prices were between $55.25 and $55.485. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. |
| 2 | Common | Common Stock | 2025-08-07 | M | A | 40,000 | $2.94 | 178,641 | D | — | — | |
| 3 | Derivative | Employee Stock Option (right to buy) | 2025-08-07 | M | D | 40,000 | $0.00 | 198,487 | D | $2.94 · — to 2029-03-11 | 40,000 Common Stock | (F3) The stock option is fully vested. |